top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Funding Activity May 6th - 10th 2024

New companies funded and major funding events…

Want to get this list of recently funded companies and more data? Fill out a quote request to get more info or set up a call (Quote Request Form)

FIG. 1. Recent Biotech Funding Activity.

Private Funding –

Zenas BioPharma

💸  Raised $200M in series C financing led by various investors to advance obexelimab development.

Bluejay Therapeutics

💸  Secured $182M in Series C co-led by Frazier Life Sciences to accelerate development of BJT-778.

Attovia Therapeutics

💸  Raised $105m in Series B financing led by Goldman Sachs Alternatives to advance its lead programs and expand the pipeline. 

Aardvark Therapeutics

💸  Completed $85M in series C funding led by Decheng Capital to advance the development of ARD-101. 

Commit Biologics

💸  Launched with €16M seed financing led by Bioqube Ventures and Novo Holdings to develop its BiCE platform to treat cancer and autoimmune disease.

Post-IPO/Public Funding –

Organon & Co.

🏦  $1B senior notes offered for secured and unsecured funding rounds at $500M each.

Verona Pharma

🏦  Announced $650M strategic financing with Oaktree and OMERS.

Pacira BioSciences, Inc.

🏦  $250M convertible senior notes offering priced at $39.56/share.

ITeos Therapeutics

🏦  Announced $120M direct offering led by RA Capital Management and Boxer Capital to extend cash runway and to initiate a Ph 3 clinical trial by 2027.

Plus Therapeutics

🏦  To raise $18M private placement w/ participation by AIGH Capital Management LLC to fund the Re-SPECT LM program.


Article History:

RF, DV, DG (05/14/24)

This article is not investment or legal advice.


bottom of page